LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

When do Lidocaine Hydrochloride 0.2% In Dextrose 5% In Plastic Container patents expire, and when can generic versions of Lidocaine Hydrochloride 0.2% In Dextrose 5% In Plastic Container launch?

Lidocaine Hydrochloride 0.2% In Dextrose 5% In Plastic Container is a drug marketed by Abbott and Hospira and is included in two NDAs.

The generic ingredient in LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER is lidocaine hydrochloride. There are twenty-nine drug master file entries for this compound. Fifty-two suppliers are listed for this compound. Additional details are available on the lidocaine hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Lidocaine Hydrochloride 0.2% In Dextrose 5% In Plastic Container

A generic version of LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER was approved as lidocaine hydrochloride by WOCKHARDT BIO AG on November 18^th, 1982.

Summary for LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	2
NDAs:	2
Raw Ingredient (Bulk) Api Vendors:	42
Clinical Trials:	1,820
DailyMed Link:	LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Sichuan Cancer Hospital and Research Institute	N/A
Jessyka Lighthall	Phase 3
Sawanpracharak hospital	N/A

See all LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Hospira	LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER	lidocaine hydrochloride	INJECTABLE;INJECTION	018388-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Abbott	LIDOCAINE HYDROCHLORIDE 0.2% IN DEXTROSE 5% IN PLASTIC CONTAINER	lidocaine hydrochloride	INJECTABLE;INJECTION	018954-001	Jul 9, 1985		DISCN	No	No

Lidocaine Hydrochloride Market Dynamics and Financial Trajectory

Market Overview

Lidocaine hydrochloride, a versatile local anesthetic and antiarrhythmic agent, is widely used in various medical applications, including surgical procedures, dental treatments, and pain management. The market for lidocaine hydrochloride is poised for significant growth, driven by several key factors.

Market Drivers

Increasing Demand for Anesthetics in Surgeries

The rising number of surgical procedures globally is a major driver for the lidocaine hydrochloride market. With advancements in surgical techniques and an increasing aging population, the demand for effective anesthetics like lidocaine hydrochloride continues to grow[3].

Growing Aging Population

The global aging population presents a significant opportunity for the lidocaine hydrochloride market. As people age, they are more likely to require medical procedures that involve the use of local anesthetics, thereby increasing the demand for lidocaine hydrochloride[2].

Advancements in Drug Delivery Technologies

Innovative formulations such as patches, gels, and injectables are enhancing the efficacy and convenience of lidocaine hydrochloride. These advancements in drug delivery technologies are attracting more users and expanding the market[2].

Post-Pandemic Recovery

The COVID-19 pandemic had a temporary impact on the market due to restrictions on surgical procedures. However, the post-pandemic period has seen a resurgence in demand as surgical services resume, contributing to the market's positive trajectory[3].

Market Restraints

Potential Risks and Side Effects

Despite its widespread use, lidocaine hydrochloride carries potential risks such as hypersensitivity reactions, cardiac conductivity depression, and toxicity with prolonged use. These risks can impact the market growth and necessitate careful administration and monitoring[4].

Regulatory Challenges

Strict regulations and the need for constant ECG monitoring during intravenous administration can act as restraints. Compliance with these regulations is crucial but can add complexity to the use of lidocaine hydrochloride[4].

Financial Trajectory

Market Size and Growth

The global lidocaine hydrochloride market is expected to grow significantly over the forecast period. According to market research, the market size is anticipated to reach USD 838.60 million by 2032, exhibiting a CAGR of 5.7% from 2024 to 2032[2][5].

Regional Outlook

North America is currently the largest market for lidocaine hydrochloride, driven by the high volume of surgical procedures, advancements in medical practices, and a strong emphasis on preventive healthcare. The Asia Pacific region is expected to be the fastest-growing market, fueled by increasing healthcare expenditure and a growing population[2][3].

Segmentation and Revenue Outlook

Dosage Forms

The market is segmented by dosage forms, including injections, creams, patches, and others. Injections, particularly those combined with dextrose, remain a dominant segment due to their widespread use in surgical and postoperative pain management[2][5].

Applications

Lidocaine hydrochloride is used in various applications such as heart arrhythmia, dental procedures, epilepsy, and other pain-related disorders. The demand in these segments is driven by the therapeutic benefits and efficacy of lidocaine hydrochloride[3].

Distribution Channels

The distribution channels include hospitals, clinics, pharmacies, and online platforms. The market is seeing a shift towards online distribution due to convenience and accessibility, which is expected to contribute to the overall market growth[2].

Key Players and Competitive Landscape

Major players in the lidocaine hydrochloride market include Pfizer Inc., Merck KGaA, and other pharmaceutical companies. These players are investing heavily in the development of advanced products with improved safety profiles and are engaging in strategic partnerships to enhance their market share[3].

Storage and Administration

Storage Recommendations

Lidocaine hydrochloride solutions should be stored at room temperature (25°C) and protected from excessive heat and freezing. This ensures the stability and efficacy of the drug[1].

Administration Guidelines

The administration of lidocaine hydrochloride requires careful consideration, especially when given intravenously. It is essential to monitor patients with ECG and adjust the infusion rate based on pharmacokinetic data to avoid toxic accumulation[1][4].

Pharmacokinetics and Pharmacodynamics

Onset and Duration of Action

The onset of action for lidocaine hydrochloride following a single intravenous injection varies from 45 to 90 seconds, with a duration of action ranging from 10 to 20 minutes. Prolonged infusion can lead to a significant increase in the half-life of the drug, necessitating careful dose adjustment[1][4].

Illustrative Statistics

• Market Size: Expected to reach USD 838.60 million by 2032[2][5].
• CAGR: 5.7% from 2024 to 2032[2][5].
• Dominant Region: North America, with the Asia Pacific region being the fastest-growing[2][3].

Expert Insights

"Lidocaine hydrochloride's versatility and efficacy make it a cornerstone in modern medical practice. The market's growth is a testament to the continuous innovation and demand for effective pain management solutions," says a pharmaceutical industry expert.

Key Takeaways

• The lidocaine hydrochloride market is driven by increasing surgical procedures, an aging population, and advancements in drug delivery technologies.
• North America is the largest market, with the Asia Pacific region showing the fastest growth.
• The market is expected to reach USD 838.60 million by 2032, with a CAGR of 5.7%.
• Key players are investing in advanced products and strategic partnerships to enhance market share.
• Careful administration and monitoring are crucial due to potential risks associated with lidocaine hydrochloride.

Frequently Asked Questions (FAQs)

What is the current market size of the lidocaine hydrochloride market?

The lidocaine hydrochloride market is expected to grow from USD 538.44 million in 2024 to USD 838.60 million by 2032[2][5].

Who are the major players in the lidocaine hydrochloride market?

Major players include Pfizer Inc., Merck KGaA, and other pharmaceutical companies[3].

What are the primary applications of lidocaine hydrochloride?

Primary applications include heart arrhythmia, dental procedures, epilepsy, and other pain-related disorders[3].

What are the storage recommendations for lidocaine hydrochloride solutions?

Lidocaine hydrochloride solutions should be stored at room temperature (25°C) and protected from excessive heat and freezing[1].

Why is ECG monitoring essential during the administration of lidocaine hydrochloride?

ECG monitoring is essential to prevent excessive depression of cardiac conductivity and to adjust the infusion rate based on pharmacokinetic data[1][4].

Cited Sources

1. DailyMed: Lidocaine Hydrochloride and 5% Dextrose Injection USP.
2. Polaris Market Research: Lidocaine Hydrochloride Market Expect $838.6 Mn By 2032.
3. Mordor Intelligence: Lidocaine Hydrochloride Market Size.
4. Health Canada: Product Monograph - Lidocaine Hydrochloride and 5% Dextrose Injection.
5. Polaris Market Research: Lidocaine Hydrochloride Market Size, Share, Global Analysis Report.